Literature DB >> 17012964

High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study.

Richard B Gearry1, Ann Richardson, Christopher M A Frampton, Judith A Collett, Michael J Burt, Bruce A Chapman, Murray L Barclay.   

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) has increased exponentially in industrialized nations over the last 50 years. Previous New Zealand studies have shown that IBD is less common than in other countries; however, clinical observations suggested a high incidence and prevalence of IBD in Canterbury, particularly Crohn's disease (CD). AIM: This study aimed to determine the descriptive epidemiology of IBD in Canterbury.
METHODS: Canterbury IBD patients, recruited using multiple strategies, gave informed consent, permission for clinical record review, completed a questionnaire, and were bled for DNA extraction as part of the Canterbury IBD Project. Cases were confirmed using standard criteria, and completeness of recruitment was validated using capture-recapture methods. Demographic and phenotypic data were extracted from case notes. One thousand four hundred twenty patients (715 CD, 668 ulcerative colitis [UC]) were recruited (> 91% of Canterbury IBD patients).
RESULTS: In 2004, age-standardized (World Health Organization World Standard Population) IBD, CD, and UC incidence rates were 25.2, 16.5, and 7.6/100,000/year, respectively. The IBD, CD, and UC point prevalences on 1 June, 2005 were 308.3, 155.2, and 145.0/100,000, respectively. CD patients were more likely than UC patients to be female (61.4% vs. 47.1%) and to be younger (median age, 39.9 years vs. 43.7 years). The percent of IBD patients who were white was 97.5%.
CONCLUSION: IBD is at least as common in Canterbury as in other western regions. CD incidence and prevalence are amongst the highest ever reported and are higher than for UC. IBD population characteristics are otherwise similar to other countries. The Canterbury IBD Project will be a valuable tool for future population-based IBD epidemiology and genetics research.

Entities:  

Mesh:

Year:  2006        PMID: 17012964     DOI: 10.1097/01.mib.0000231572.88806.b9

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  50 in total

Review 1.  An update of the role of nutritional therapy in the management of Crohn's disease.

Authors:  Moftah H Alhagamhmad; Andrew S Day; Daniel A Lemberg; Steven T Leach
Journal:  J Gastroenterol       Date:  2012-06-15       Impact factor: 7.527

2.  Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics.

Authors:  Eun Soo Kim; Won Ho Kim
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

Review 3.  Mycobacterium paratuberculosis as a cause of Crohn's disease.

Authors:  Adrienne L McNees; Diane Markesich; Najah R Zayyani; David Y Graham
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-10-16       Impact factor: 3.869

Review 4.  Crohn's disease: a clinical update.

Authors:  Francis Ha; Hanan Khalil
Journal:  Therap Adv Gastroenterol       Date:  2015-11       Impact factor: 4.409

5.  Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk.

Authors:  Lynnette R Ferguson; Claudia Huebner; Ivonne Petermann; Richard B Gearry; Murray L Barclay; Pieter Demmers; Alan McCulloch; Dug Yeo Han
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

Review 6.  Advances in epidemiology and diagnosis of inflammatory bowel diseases.

Authors:  Sobia Ali; Cyrus P Tamboli
Journal:  Curr Gastroenterol Rep       Date:  2008-12

7.  An envirogenomic signature is associated with risk of IBD-related surgery in a population-based Crohn's disease cohort.

Authors:  Bushra F Nasir; Lyn R Griffiths; Aslam Nasir; Rebecca Roberts; Murray Barclay; Richard B Gearry; Rodney A Lea
Journal:  J Gastrointest Surg       Date:  2013-07-02       Impact factor: 3.452

Review 8.  Inflammatory bowel diseases: a disease (s) of modern times? Is incidence still increasing?

Authors:  Cristina Saro Gismera; Beatriz Sicilia Aladrén
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

9.  The prevalences of some rheumatic diseases in western Turkey: Havsa study.

Authors:  Necati Cakır; Ömer Nuri Pamuk; Emine Derviş; Neşe Imeryüz; Haşim Uslu; Ömer Benian; Edip Elelçi; Genco Erdem; Fatma Oğuz Sarvan; Mustafa Senocak
Journal:  Rheumatol Int       Date:  2011-01-13       Impact factor: 2.631

10.  Immunomodulation does not alter histology in resected Crohn's disease.

Authors:  F A Frizelle; A Ing; R B Gearry; M Whitehead; I G Faragher; B Dobbs
Journal:  Tech Coloproctol       Date:  2009-09-23       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.